European consensus in questions about atherogenic dyslipidemia and combination of statine and obrate
Abstract
Atherogenic dyslipidemia (AD), characterized by increased triglycerides in the context of the reduction in HDL-cholesterol (HDL-c), has been in the center of our attention for quite some time. Epidemiological trends, new knowledge about the importance of AD as well as the possibilities of its management led to the formulation of a consensus of European experts on this issue.
AD regularly accompanies conditions associated with insulin resistance. Non-HDL-cholesterol and apolipoprotein B concentrations appear to be suitable markers of cardiovascular risk in patients with AD and, also, therapeutic targets.
The question of remnant lipoproteins and their role in determining cardiovascular risk, especially in patients with AD, has gained special attention. Treatment is based on a rigorous diet and lifestyle modification.
Pharmacological therapy is based on statins. In patients with hypertriglyceridemia and persistent unsatisfactory control of non-HDL-C a combination with fenofibrate should be considered.
In this situation this combination further reduces the risk of macrovascular and microvascular complications.